New drug COM503 enters first human trial for advanced cancers
NCT ID NCT06759649
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests a new drug called COM503, alone or with another drug zimberelimab, in 200 people with advanced solid tumors that have not responded to standard treatments. The main goal is to check safety and find the right dose. It is a first-in-human study, so effectiveness is not yet known.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
COM503 (a drug given by IV) and zimberelimab (another drug given by IV)
What this could lead to
If it works, this could point toward a new treatment option for people with advanced solid tumors who have run out of standard therapies.
What could go wrong
This is a very early Phase 1 trial, so the main goal is safety, not effectiveness. It may not work, and side effects are unknown. Only 200 people are enrolled, so results may not apply to everyone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOPLASM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beth Israel Deaconess Medical Center
RECRUITINGBoston, Massachusetts, 0221502215, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hadassah University Medical Center- Ein Kerem
RECRUITINGJerusalem, Israel, 9112001, Israel
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
NEXT Oncology San Antonio
RECRUITINGSan Antonio, Texas, 78229, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
NEXT Oncology Virginia
RECRUITINGFairfax, Virginia, 22031, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Rabin Medical Center
RECRUITINGPetah Tikva, Israel, 4941492, Israel
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Rambam Health Care Campus
RECRUITINGHaifa, Israel, 3109601, Israel
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
START
RECRUITINGSan Antonio, Texas, 78229, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
START Midwest
RECRUITINGGrand Rapids, Michigan, 49546, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The Chaim Sheba Medical Center
RECRUITINGRamat Gan, Israel, 5465601, Israel
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The West Clinic, PLCC dba West Cancer Center
RECRUITINGGermantown, Tennessee, 38138, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Yale- New Haven Hospital- Yale Cancer Center
RECRUITINGNew Haven, Connecticut, 06510, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••